Reduction of immunosuppressive intensity is the first step in management, but the Kidney Disease Improving Global Outcomes (KDIGO) recommendations suggest that treatment with an mTOR inhibitor also be started [53]. The gene discussed is MTOR; the disease is medical procedure.